BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23668209)

  • 1. [Clinical and laboratory features of four cases with IgM multiple myeloma].
    Fan JL; Fu WJ; Shi HT; Zhou F; Yuan ZG; Zhang CY; Wei W; Ye F; Zhang H; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):341-4. PubMed ID: 23668209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunoglobulin M multiple myeloma: a six-case report and literature review].
    Yan WW; Fan HS; Xu JY; Liu JH; Du CX; Deng SH; Sui WW; Xu Y; Qiu LG; An G
    Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):1011-1014. PubMed ID: 35045672
    [No Abstract]   [Full Text] [Related]  

  • 3. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
    Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
    Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgM plasma cell myeloma in the era of novel therapy: a clinicopathological study of 17 cases.
    Angelova EA; Li S; Wang W; Bueso-Ramos C; Tang G; Medeiros LJ; Lin P
    Hum Pathol; 2019 Feb; 84():321-334. PubMed ID: 30266252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
    Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
    Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical characteristics and prognosis of IGH deletion in multiple myeloma.
    He H; Fu W; Jiang H; Du J; Zhou L; Zhang C; Xi H; Li R; Hou J
    Leuk Res; 2015 May; 39(5):515-9. PubMed ID: 25817540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Investigation of 1q21 amplification in patients with multiple myeloma using I-FISH and cIg-FISH].
    Yang RF; Li CM; Qiu HR; Lu H; Wu HX; Xu JR; Zhang P; Li JY; Chen LJ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Dec; 28(6):686-9. PubMed ID: 22161106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
    Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
    Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14).
    Feyler S; O'Connor SJ; Rawstron AC; Subash C; Ross FM; Pratt G; Drayson MT; Ashcroft J; Cook G; Owen RG
    Br J Haematol; 2008 Mar; 140(5):547-51. PubMed ID: 18275432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA T-cell factor 7 in multiple myeloma: A potential biomarker for deteriorated clinical features and poor prognosis.
    Zhang C; Chu M; Fan Y; Wu L; Li Z; Ma X; Zhuang W
    J Clin Lab Anal; 2020 Sep; 34(9):e23400. PubMed ID: 32578294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of the efficacy and prognosis on first-line autologous hematopoietic stem cell transplantation of patients with multiple myeloma].
    Zou DH; Sui WW; Yi SH; An G; Xu Y; Li ZJ; Li CW; Qi JY; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):299-303. PubMed ID: 23668200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
    Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
    Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of Chromosome Abnormality on Therapeutic Efficacy and Prognosis of Newly Diagnosed Multiple Myeloma Treated with Bortezomib].
    Sun C; Wang J; Guo HF; Zhou X; Shen YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):142-146. PubMed ID: 28245391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgM myeloma: A multicenter retrospective study of 134 patients.
    Castillo JJ; Jurczyszyn A; Brozova L; Crusoe E; Czepiel J; Davila J; Dispenzieri A; Eveillard M; Fiala MA; Ghobrial IM; Gozzetti A; Gustine JN; Hajek R; Hungria V; Jarkovsky J; Jayabalan D; Laubach JP; Lewicka B; Maisnar V; Manasanch EE; Moreau P; Morgan EA; Nahi H; Niesvizky R; Paba-Prada C; Pika T; Pour L; Reagan JL; Richardson PG; Shah J; Spicka I; Vij R; Waszczuk-Gajda A; Gertz MA
    Am J Hematol; 2017 Aug; 92(8):746-751. PubMed ID: 28383205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.
    El-Ghammaz AM; Abdelwahed E
    Ann Hematol; 2016 Aug; 95(8):1315-21. PubMed ID: 27184486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
    Bianchi G; Richardson PG; Anderson KC
    J Clin Oncol; 2014 Jul; 32(20):2125-32. PubMed ID: 24888801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome.
    An G; Xu Y; Shi L; Zou D; Deng S; Sui W; Xie Z; Hao M; Chang H; Qiu L
    Leuk Res; 2013 Oct; 37(10):1251-7. PubMed ID: 23927993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia.
    Avet-Loiseau H; Garand R; Lodé L; Robillard N; Bataille R
    Semin Oncol; 2003 Apr; 30(2):153-5. PubMed ID: 12720126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
    An G; Li Z; Tai YT; Acharya C; Li Q; Qin X; Yi S; Xu Y; Feng X; Li C; Zhao J; Shi L; Zang M; Deng S; Sui W; Hao M; Zou D; Zhao Y; Qi J; Cheng T; Ru K; Wang J; Anderson KC; Qiu L
    Clin Cancer Res; 2015 May; 21(9):2148-56. PubMed ID: 25652456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.